x

Posted 06 October, 2023

FIBROGEN INC appointed Thane Wettig as new CEO

Nasdaq:FGEN appointed new Chief Executive Officer Thane Wettig in a 8-K filed on 06 October, 2023.


  On October 2, 2023, the Board of Directors (the "Board") of FibroGen, Inc. (the "Company") appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of FIBROGEN INC
Health Care/Life Sciences • Biotechnology
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
Market Cap
$196M
View Company Details
FIBROGEN INC by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Appointment of Chief Executive Officer, Director


On October 2, 2023, the Board of Directors (the "Board") of FibroGen, Inc. (the "Company") appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board. Mr. Wettig was appointed as a Class I director for the term expiring at the Company's 2024 annual meeting of stockholders. Mr. Wettig held the position of Interim Chief Executive Officer since July 23, 2023, and he will continue to receive the compensation described in the Form 8-K as filed with the Securities and Exchange Commission on July 25, 2023 regarding his appointment as Interim Chief Executive Officer.